MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

NCT00070837 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: MLN2704 (DM1 conjugated monoclonal antibody MLN591)

Sponsor

Millennium Pharmaceuticals, Inc.